Research programme: drug discovery - Astellas Pharma/Daiichi Sankyo
Latest Information Update: 01 Apr 2014
At a glance
- Originator Astellas Pharma; Daiichi Sankyo Company
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 01 Apr 2014 Early research in Undefined indication in Japan (unspecified route)